Asston Pharmaceuticals has scheduled its seventh annual general meeting for September 29, 2026. The meeting will address key governance matters, including the re-appointment of the managing director and significant remuneration increases for senior leadership.

The company’s board of directors met on September 4, 2026 to approve these changes. The AGM will be conducted via Video Conferencing and Other Audio Visual Means. M/s Pragya & Associates has been appointed as the scrutinizer for the meeting.

Remuneration Increases

The board proposed special resolutions to increase the monthly remuneration for three key executives, effective from October 1, 2026 through September 30, 2029. These increases require shareholder approval at the AGM.

Mr. Sakalkar, who is retiring by rotation, is also seeking re-appointment as Managing Director. The resolutions note that these payments will continue even if the company reports no profits or inadequate profits during the tenure, subject to statutory approvals under Schedule V of the Companies Act, 2013.

Auditor Appointment

The company appointed M/s Panchal S K & Associates as its statutory auditor for a term of five years, commencing from the conclusion of the current AGM until the conclusion of the 12th AGM. The proposed fees are ₹5,00,000 excluding taxes and out-of-pocket expenses. M/s Yash A. Jain & Associates was appointed as internal auditor.

Financial Performance Context

The explanatory statement accompanying the notice highlights the company’s financial performance for FY26. Gross turnover stood at ₹3158.43 lakh, with profit before interest, depreciation and tax (PBIT) at ₹555.01 lakh. Net profit for the period was ₹386.52 lakh.

AGM Logistics

The cut-off date for determining eligible shareholders for e-voting is September 22, 2026. Remote e-voting will be facilitated by National Securities Depository Limited (NSDL), beginning on September 26, 2026 and ending on September 28, 2026.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0SJX01015/dab3a30d-ecba-411f-a722-4a951933ab07.pdf

Asston Pharmaceuticals approved the preferential allotment of 24,10,431 equity shares at ₹115 per share on September 5, 2026. The issuance raises the company’s paid-up equity capital to ₹10.92 crore.

The Board of Directors sanctioned the allotment during a meeting that commenced at 10:30 am and concluded at 10:45 am. The shares carry a face value of ₹10 each, with a premium of ₹105 per share payable in cash.

Allotment Details

The company allotted shares to 15 investors, all categorized as public allottees. Vijay Rathee emerged as the largest recipient, acquiring 13,17,391 shares. Vijaylaxmi Infra Projects Private Limited received the second-largest allocation of 7,82,608 shares.

Consequent to this allotment, the total number of equity shares stands at 1,09,22,791. The newly allotted shares rank pari passu in all respects with existing equity shares.

What the Numbers Show

The concentration of allotment is notable, with the top two investors—Vijay Rathee and Vijaylaxmi Infra Projects Private Limited—accounting for approximately 85% of the total shares issued in this round. This suggests significant interest from specific large stakeholders rather than broad-based retail participation.